Nasdaq Dip & Rip

[fitzkarz]

Provectus News

Provectus Biopharmaceuticals Expands Global Patent Portfolio for Active Pharmaceutical Ingredient Manufacture

Tuesday June 19, 2018

KNOXVILLE, TN, /GLOBE NEWSWIRE/ -- Provectus today announced that the Indian Patent Office (IPO) has granted the Company's patent application for the synthetic process used to produce the active pharmaceutical ingredient (API) in PV-10, which is Provectus' lead investigational oncology drug. The Company's patent estate associated with API manufacturing provides intellectual property protection in a number of countries in Asia, Europe, and North America into the 2030s.

IPO patent 297453 is linked to U.S. patent (USP) 8,530,675, entitled "Process for the Synthesis of 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodo-3H-spiro[isobenzofuran-1,9-xanthen]-3-one (Rose Bengal) and Related Xanthenes," which was awarded by the United States Patent and Trademark Office (USPTO) in 2013. The Company received related awards from, among others, the European Patent Office (EPO), the Japan Patent Office (JPO), and the State Intellectual Property Office (SIPO or the Chinese Patent Office) in 2015.

Continuations of Provectus' foundational manufacturing patent include USP 9,273,022 and USP 9,422,260, which were awarded by the USPTO in 2016.

Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) (Provectus or the Company) is a clinical-stage biotechnology company developing PV-10 as the first small molecule oncolytic immunotherapy for solid tumor cancers in adults and children.

The complete press release is available at https://www.provectusbio.com/news/press-releases/provectus-pr-20180619-1 on the Provectus website.